Indicated for: spasticity; dystonias; neuromuscular disorders
Route of administration: injectable
Substance: botulinum toxin type A (botulinum toxin)
ATC: M03AX01 (Musculo-skeletal system | Muscle relaxants, peripherally acting agents | Other muscle relaxants, peripherally acting agents)
Botulinum toxin type A is a neurotoxin produced by the bacterium Clostridium botulinum, widely used for both therapeutic and cosmetic purposes. In medicine, it is indicated for the treatment of cervical dystonia, spasticity, chronic migraines, hyperhidrosis, and other conditions associated with excessive muscle activity.
Botulinum toxin type A works by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation. It is administered via local injections, with effects typically appearing within a few days and lasting between 3 and 6 months, depending on the indication.
Common side effects include injection site pain, localized muscle weakness, headache, and flu-like symptoms. In rare cases, severe adverse reactions such as difficulty breathing or swallowing may occur. It is essential that treatment is performed by a qualified specialist to minimize risks.
Botulinum toxin type A is a versatile and effective therapeutic option, contributing to symptom relief and improved quality of life for patients.